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ABSTRACT
Objectives: For the purpose of blocking transmission
of Plasmodium falciparum malaria from humans to
mosquitoes, a single dose of primaquine is
recommended by the WHO as an addition to artemisinin
combination therapy. Primaquine clears gametocytes but
causes dose-dependent haemolysis in individuals with
glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Evidence is needed to inform the optimal dosing of
primaquine for malaria elimination programmes and for
the purpose of interrupting the spread of artemisinin-
resistant malaria. This study investigates the efficacy and
safety of reducing doses of primaquine for clearance of
gametocytes in participants with normal G6PD status.
Methods and analysis: In this prospective, four-
armed randomised placebo-controlled double-blinded
trial, children aged 1–10 years, weighing over 10 kg, with
haemoglobin ≥8 g/dl and uncomplicated P falciparum
malaria are treated with artemether lumefantrine and
randomised to receive a dose of primaquine (0.1, 0.4 or
0.75 mg base/kg) or placebo on the third day of
treatment. Participants are followed up for 28 days.
Gametocytaemia is measured by quantitative nucleic acid
sequence-based analysis on days 0, 2, 3, 7, 10 and 14
with a primary endpoint of the number of days to
gametocyte clearance in each treatment arm and
secondarily the area under the curve of gametocyte
density over time. Analysis is for non-inferiority of
efficacy compared to the reference dose, 0.75 mg
base/kg. Safety is assessed by pair-wise comparisons
of the arithmetic mean (±SD) change in haemoglobin
concentration per treatment arm and analysed for
superiority to placebo and incidence of adverse events.
Ethics and dissemination Approval was obtained from the
ethical committees of Makerere University School of
Medicine, the Ugandan National Council of Science and
Technology and the London School of Hygiene and
Tropical Medicine.
Results: These will be disseminated to inform malaria
elimination policy, through peer-reviewed publication and
academic presentations.
BACKGROUND
Sustained deployment of vector control mea-
sures and accessible, effective drug therapy has
ARTICLE SUMMARY
Article focus
▪ Single-dose primaquine, administered together
with artemisinin combination therapy, blocks
transmission of Plasmodium falciparum malaria
by clearing gametocytes.
▪ Primaquine, an 8-aminoquinoline, causes dose-
dependent haemolysis in individuals with
glucose-6-phosphate dehydrogenase (G6PD)
deficiency. Evidence is lacking on the safety
and efficacy of lower doses of primaquine.
▪ This is the protocol of a dose-finding trial being
conducted in eastern Uganda.
Key messages
▪ Dose-finding is a priority for the use of prima-
quine in malaria elimination programmes and to
block the spread of artemisinin-resistant malaria.
▪ This trial is designed to investigate the efficacy
and safety of reducing doses of primaquine for
gametocytocidal action.
▪ This paper highlights the unique trial design
issues that are relevant for investigating the effi-
cacy and safety of antimalarials targeted against
the sexual stages of malaria for blocking trans-
mission rather than clinical cure.
Strengths and limitations of this study
▪ For ethical reasons, in this trial, dose-finding is
conducted in children with normal G6PD status,
but, ultimately, information is needed on the safety
of lower doses in people with G6PD deficiency.
▪ This trial measures primaquine’s transmission-
blocking potential by assessing gametocyte
clearance. Endpoints of mosquito transmission at
multiple time points could be usefully assessed
but on smaller numbers of individuals.
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reduced the transmission of Plasmodium falciparum in many
endemic countries. However, further scaling-up of cur-
rently available malaria control measures is unlikely to
achieve malaria elimination in most settings.1 Moreover,
the emergence of resistance to artemisinin in Southeast
Asia,2 3 and the development of insecticide resistance and
adaptive behaviour in the mosquito vector4–6 present sig-
niﬁcant threats to the current trend of declining malaria
burden. Malaria elimination initiatives and artemisinin-
resistance containment strategies both require additional
tools that are speciﬁcally aimed at reducing the transmis-
sion of malarial parasites.7 8
Antimalarial drugs are designed primarily to target
the asexual stages of the parasite that cause morbidity
and mortality. The effect of antimalarial drugs on game-
tocytes, the transmission stages, has for decades been
seen as ancillary. P falciparum gametocytes undergo
complex development that is characterised by ﬁve mor-
phologically distinct stages of maturation.9 The imma-
ture gametocyte stages (I–IV) are sequestered in the
reticuloendothelial system and bone marrow.10–12
Mature stage V gametocytes typically appear approxi-
mately 12 days after the onset of patent asexual blood-
stream infection, and are the only gametocyte stage that
circulates in the peripheral blood and is infective to
biting female Anopheles mosquitoes.13 14 The majority of
antimalarial drugs, including artemisinins, lumefantrine
and piperaquine, have some efﬁcacy against immature
gametocytes.15 16 These drugs have the potential to
reduce transmission at a population level because
asexual parasites are cleared, preventing de novo devel-
opment of gametocytes, and fewer of the immature
gametocytes that are present upon initiation of treat-
ment survive to maturity. However, the vast majority of
symptomatic cases have measurable and transmissible
levels of mature gametocytes at presentation.17 18 These
persist after treatment with all antimalarials that are cur-
rently implemented as ﬁrst-line treatment, including
artemisinin combination therapy (ACT). Gametocytes
that persist after ACT have repeatedly been shown to be
infectious to mosquitoes.17 19 20 This post-treatment
gametocyte carriage frequently occurs at low densities,
commonly below the microscopic threshold for detec-
tion,21 22 but is sufﬁciently high for efﬁcient mosquito
infection.17 23
The only class of drugs that are effective against mature
P falciparum gametocytes is the 8-aminoquinolines.
Primaquine is the most widely available drug in this class.
The exact mechanism for this gametocytocidal activity is
unknown, but it is probably dependent on oxidative
damage to the intraerythrocytic parasite by primaquine
metabolites.24 Primaquine as a single dose of 0.75 mg
base/kg added to standard ACT has superior gametocyto-
cidal activity to ACT alone.25–27 All doses of primaquine
described hereafter refer to the dose of primaquine base
per unit weight. There are indications that doses of
primaquine lower than 0.75 mg/kg may be equally efﬁca-
cious. A Thai study showed that both 0.5 and 0.25 mg/kg
of primaquine administered with ACT to adults infected
with malaria effectively and indistinguishably reduced the
proportion of mosquitoes that became infected after a
blood meal.28 In small numbers of adults, total doses of
30 mg and 15 mg have shown comparable efﬁcacy to a
45 mg dose in reducing mosquito infection rates.29 30
The efﬁcacy of primaquine when given as a single low
dose is important in the light of concerns over the
haematological safety of primaquine. There is conclusive
evidence for primaquine-induced haemolysis in
glucose-6-phosphate dehydrogenase (G6PD) deﬁcient
individuals.31 32 G6PD deﬁcient individuals are vulner-
able to oxidative stress because their erythrocytes do not
have alternative pathways for G6PD-dependent nicotina-
mide adenine dinucleotide phosphate production,
which is essential to maintain antioxidant defences.
There is conﬂicting evidence on the risk of haemolysis
after a single dose of primaquine. A single dose of
45 mg primaquine administered to a Vanuatan adult
caused life-threatening haemolysis.33 In G6PD-deﬁcient
Tanzanian children, the mean fall in haemoglobin after
a single dose of 0.75 mg/kg primaquine was 2.5 g/dl
(95% CI 1.2 to 3.8 g/dl), though no associated severe
adverse events were recorded and haemolysis was
transient.34 On the other hand, primaquine was
reported to be well tolerated when 0.75 mg/kg was given
without prior G6PD testing in large studies in Myanmar,
Sudan, Russia, Cambodia and China.27 31 35 36
Because primaquine-induced haemolysis is dose-
dependent,29 and because gametocytocidal efﬁcacy may
be retained with primaquine doses lower than
0.75 mg/kg, the WHO-recommended dose in its 2010
Guidelines for the Treatment of Malaria, dose-ﬁnding
studies are needed urgently. This trial tests the hypoth-
esis that lower doses of primaquine have a substantially
lower risk of, or an absence of, adverse effects but that
their gametocytocidal efﬁcacy is retained.
METHODS AND ANALYSIS
Study design
The study is a prospective, randomised, parallel arm,
placebo-controlled, double-blinded clinical trial of redu-
cing doses of primaquine administered with artemether
lumefantrine (AL) for the treatment of uncomplicated
clinical P falciparum malaria infection in children aged
1–10 years of age. The study uses a non-inferiority
design to evaluate the efﬁcacy and a superiority design
to evaluate the safety of 0.1 and 0.4 mg/kg primaquine
compared with 0.75 mg/kg when added to AL.
Study objectives
1. To evaluate the efﬁcacy of 0.1, 0.4 and 0.75 mg/kg
primaquine when administered together with the
ﬁfth dose of AL as measured by gametocyte preva-
lence and density.
2. To evaluate the safety of 0.1, 0.4 and 0.75 mg/kg
primaquine when administered together with the
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ﬁfth dose of AL as measured by change in mean
haemoglobin, prevalence of severe anaemia
(haemoglobin <5 g/dl) and evidence of black urine
(haemoglobinuria).
3. To assess the safety of different doses of 0.1, 0.4 and
0.75 mg/kg primaquine when administered together
with the ﬁfth dose of AL as measured by preva-
lence/incidence of adverse events and tolerability.
Participants and enrolment
The study is conducted at Walukuba Health Centre IV
in Walukuba subcounty, Jinja district, in eastern Uganda.
In this area, malaria transmission is year-round with two
seasonal peaks. The entomological inoculation rate
(EIR) was estimated at 7 infectious bites per person per
year in Walukuba.37 Study participants are recruited
from children attending the Health Centre IV with sus-
pected malaria (ﬁgure 1). Inclusion criteria are age
1–10 years, weight over 10 kg, fever (tympanic tempera-
ture >38°C) or history of fever in the last 24 h, P falcip-
arum mono-infection with a parasite density <5 00 000/
µl and normal G6PD enzyme function. Exclusion cri-
teria are evidence of severe illness/danger signs, known
allergy to study medications, haemoglobin <8 g/dl,
started menstruation, pregnancy or breastfeeding, anti-
malarials taken within the last 2 days, primaquine taken
within the last 4 weeks and blood transfusion within the
last 90 days.
The ﬂuorescent spot test38 is used for G6PD screen-
ing. This test has a cut-off of approximately 20% enzyme
function, below that, there is no ﬂuorescence. The
WHO classiﬁcation deﬁnes severe G6PD deﬁciency as
10% enzyme function.39
Randomisation, blinding and intervention
After enrolment (day 0), participants are randomised to
a treatment arm stratiﬁed by gender (ﬁgure 2). The
study pharmacist selects sequential opaque envelopes
(from either the male or the female pile). Each enve-
lope contains a predetermined treatment assignment
code. The study pharmacist is the only member of the
clinic team not blinded to the treatment arm and is not
involved in assessing patients or assigning outcomes. All
study site staff who administer drugs, assess patients and
process laboratory samples do not have access to the ran-
domisation code breaker.
All participants receive a 3 day course of artemether
lumefantrine according to Ugandan national treatment
guidelines for uncomplicated malaria. Participants are ran-
domised to receive a placebo or a dose of 0.1, 0.4 or
0.75 mg/kg primaquine in addition to the AL treatment.
The dose of primaquine/placebo is given at the same time
as the ﬁfth dose of AL, in the morning of day 2. To pre-
serve the accuracy of lower weight-based doses, all prima-
quine doses are administered in aqueous solution and
measured using a sterile syringe. The placebo is aqueous
solution alone. All doses including placebo are mixed with
glucose-based syrup that masks the colour and taste of
primaquine. All treatments are directly observed. A snack
with approximately 5 g of fat is administered prior to both
AL and primaquine administration to optimise absorption
of AL and minimise gastrointestinal side effects with
primaquine. Participants are observed for 30 minutes;
treatment is readministered in any case of vomiting within
this period. Repeated vomiting (>3 times) leads to exclu-
sion from the study and treatment as complicated malaria
according to national guidelines.
Figure 1 Enrolment and
selection procedures.
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Follow-up measurements
Study participants are reviewed on days 0, 1, 2, 3, 7, 10, 14,
21 and 28 after enrolment or on any day of illness. On
each of the scheduled visit days they are assessed clinically
with standardised adverse event recording and blood
samples are taken for microscopical detection of asexual
parasites and gametocytes, molecular detection of gameto-
cytes and haemoglobin measurements (table 1).
Blood smears from all visits are Giemsa-stained and 100
microscopic ﬁelds are screened for asexual parasites on
days 0, 1, 2, 3, 7, 10, 14, 21 and 28. Asexual parasites are
counted against 200 white blood cells (WBC) or, if fewer
than 10 parasites are observed per 200 WBC, against 500
WBC. Gametocytes are recorded if observed during
this screening process. On day 0, 100 microscopic ﬁelds
are reread for gametocytes speciﬁcally. If gametocytes are
observed, they are quantiﬁed against 500 WBC. All micros-
copy readings are performed by two independent micro-
scopists, if they disagree on prevalence or if density results
differ by more than 25%, a third reading is requested.
Gametocytes are quantiﬁed on days 0, 2, 3, 7, 10 and
14 using quantitative real-time nucleic acid sequence-
based analysis (QT-NASBA), detecting and quantifying
Pfs25 mRNA. One hundred microlitres of ﬁnger prick
blood is mixed with 900 µl L6 guanidine buffer (Severn
Biotech, UK) and stored at −80°C until automatic
nucleic acid extraction by MagNAPure (Roche) using
commercial high-yield kits. The Pfs25 QT-NASBA is spe-
ciﬁc for mature gametocytes with a sensitivity of 0.01–0.1
gametocytes/µl of blood when 50 µl blood samples are
used for RNA extraction.40
Haemoglobin is measured on days 0, 1, 2, 3, 7, 10, 14,
21 and 28 using HemoCue 201+ photometers
(HemoCue; Angelholm, Sweden). At each follow-up visit,
study staff assess participants in an objective manner
according to a clinical record form and assessment for
adverse events is conducted in a prospective, systematic
fashion during all visits, including the enrolment visit
(eg, vomiting post-AL). All data are double-entered in
real time.
Safety considerations
A protocol was developed in order to standardise the
detection, investigation and management of severe haem-
olysis in this trial (ﬁgures 3 and 4). A Data Safety
Monitoring Board (DSMB) has been installed; clinically
relevant haemolytic events, hospital admissions, blood
transfusions and deaths are reported within 72 h to this
DSMB.
Ethical considerations
The study protocol and informed consent forms were
approved by the Makerere University School of
Medicine Research Ethics Committee (protocol 2011–
210), the Uganda National Council of Science and
Technology (protocol HS1056) and the London School
of Hygiene and Tropical Medicine research ethics com-
mittee (protocol 5987). The Ugandan National Drug
Authority approved the protocol and importation of
primaquine for the purposes of the study. The DSMB
and Trial Advisory Committee for the study agreed to
meet at predetermined stages of the study. Before the
study began, local community stakeholders (including
village health team and local council members) in
Walukuba were consulted and a community advisory
board meeting was held.
Sample size
For efﬁcacy, the sample size calculation is based on
non-inferiority of each of the two test dose arms to the
comparator arm, the WHO-recommended dose of
primaquine, 0.75 mg/kg. The primary outcome
Figure 2 Participant flow
diagram.
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measure is number of days to gametocyte clearance.
The addition of primaquine (0.75 mg/kg) to ACT in
Tanzania reduced the time to gametocyte clearance
from 28.6 to 6.3 days (SD 6 days).41 Allowing for a 10%
loss to follow-up, a sample size of 120/arm will provide
over 80% power at the 0.05 signiﬁcance level to detect
non-inferiority to the standard arm with a non-
inferiority margin of 2.5 days, which was considered to
be a clinically relevant reduction in gametocyte clear-
ance time. This sample size also allows for an analysis
of superiority of the efﬁcacy of the two test dose arms
to placebo.
For safety, the sample size calculation is based on
superiority of each of the two test dose arms to the com-
parator arm (0.75 mg/kg). For this comparator arm,
Shekalaghe et al34 found an overall mean absolute drop
in haemoglobin by day 7 after treatment of 0.6 g/dl (SD
1.5). Therefore, with 80% power and at the 0.05 signiﬁ-
cance level, a sample size of 99 would be required to
detect a difference in mean maximal drop in haemoglo-
bin between treatment groups of 0.6 g/dl.
Data analysis
Data will be double entered in Microsoft Access and
imported into Stata V.12.0 (Statacorp Ltd, Texas, USA).
All efﬁcacy analyses will be based on gametocyte detec-
tion by Pfs25 QT-NASBA. Gametocyte density on days 7,
10 and 14 will be compared with the comparator arm
(0.75 mg primaquine/kg) by χ2 test. The mean duration
of gametocyte carriage and 95% CI will be estimated in
each treatment arm and compared with the comparator
arm using a previously validated mathematical model.42
The area under the curve of gametocyte density over
time will be calculated using the method described by
Mendez et al43 For individuals who are gametocyte posi-
tive at enrolment, Kaplan-Meier survival analysis will be
used to compare the decline in gametocyte prevalence.
Table 1 Summary of outcome measures
Outcome measure Description
Efficacy
Primary Mean number of days to gametocyte clearance
(GCT)
Mean number of days per treatment arm for
gametocytes to become undetectable using
submicroscopic molecular testing methods (QT-NASBA).
Reappearance of gametocytes after day 14 will be
considered as re-infection and excluded
Secondary Mean (±SD) area under the curve of gametocyte
density per day during 14 days of follow-up
Total number of gametocytes (measured by QT-NASBA)
seen over follow-up, averaged per day of follow-up (days
0–14)
Density of gametocytes on days 7, 10 and 14 Mean number of gametocytes (measured by
QT-NASBA) per treatment arm on days 7, 10 and 14
Proportion (%) of participants with gametocytes on
each day of follow-up
For each treatment arm, percentage of participants with
gametocytes (measured by QT-NASBA) on each day of
follow-up from days 0–14
Safety
Primary Mean (± SD) maximal fall (±) in Hb (haemoglobin,
g/dl) from enrolment to day 28 of follow-up
Mean maximal greatest negative difference in Hb
(measured by HemoCue) from enrolment value per
treatment arm over 28 days follow-up
Secondary Follow-up day of Hb nadir Mean day of follow-up (day 0–28) per treatment arm of
lowest Hb measurement (by HemoCue)
Maximal percentage fall in Hb level compared to
enrolment value
Size of maximal Hb drop (by HemoCue) during follow-up
(day 0–28) from enrolment value, divided by enrolment
value, *100
Percentage of participants with Hb<5 g/dl during
follow-up
Percentage (number) per treatment arm during days
0–28
Requirement for blood transfusion Percentage (number) of children receiving blood
transfusion per treatment arm during days 0–28
Evidence of black urine Percentage (number) of children with documented black/
dark urine with urine dipstick positive for Hb per
treatment arm during days 0–28
Incidence of serious adverse events by sign,
symptom, laboratory parameter and relationship to
taking study drug
Percentage (number) per treatment arm during days
0–28
Incidence of gastrointestinal symptoms after taking
study drug
Percentage (number) per treatment arm during days 2–7
GCT, gametocyte clearance time; Hb, haemoglobin; QT-NASBA, quantitative real-time nucleic acid sequence-based analysis.
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The primary safety outcome, mean maximal fall in
haemoglobin concentration during 28 days of follow-up
will be assessed for each treatment arm. Pair-wise com-
parisons will be made between each of the treatment
arms and compared with the comparator arm using
unpaired t tests.
DISCUSSION
In the 2010 edition of the Guidelines for the
Treatment of Malaria, the WHO recommends that
a single dose of 0.75 mg/kg primaquine is added to
ACT in malaria elimination programmes and for
epidemic control, provided the risks of haemolysis in
G6PD-deﬁcient patients are considered. This guidance
was recently updated to recommend a lower dose of
0.25 mg/kg primaquine without G6PD testing for new
malaria elimination programmes and to prevent the
spread of artemisinin resistance.31 The revision was
based largely on grey literature and historical data
rather than on recent clinical trials and few of the data
are in the public domain.44 There have been no formal
dose-ﬁnding studies using contemporary tools and stan-
dards for the measurement of drug efﬁcacy and safety
for the combination of ACTs and primaquine. In the
current study, we aim to provide these urgently needed
efﬁcacy data and provide safety data for individuals with
normal G6PD enzyme function.
Figure 4 Procedure for
management of haemolysis.
Figure 3 Procedure for
investigation of suspected
haemolysis.
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Relatively few trials have been designed speciﬁcally to
test gametocytocidal drugs in vivo. Standardised proto-
cols and trial designs for assessing the efﬁcacy of drugs
targeted against asexual parasites45 46 are not suitable to
assess gametocytocidal drugs, where the main outcome
is transmission-blocking activity rather than clinical or
parasitological cure. There is no agreement on the best
tools to quantify gametocyte carriage. Many trials have
used microscopy to measure gametocytes26–28 47 48 while
it has been known for decades that microscopy is notori-
ously insensitive for detecting gametocytes.49
Gametocytes typically circulate at densities that are ≤1%
of asexual parasite densities.16 50 Nevertheless, gameto-
cytes are often simply recorded while screening for
asexual parasites. If slides are speciﬁcally read for game-
tocytes, the number of microscopic ﬁelds that is
screened is mostly the same as that for asexual para-
sites.51 As a consequence, gametocytes measured micro-
scopically by routine underestimate the total gametocyte
prevalence by up to 10-fold.16 17 21 22 In the current
study, gametocytes are quantiﬁed with the most widely
used quantitative molecular gametocyte detection
method, QT-NASBA that has an estimated sensitivity of
0.01–0.1 gametocytes/µl blood in the blood sample
taken.40 The use of this sensitive molecular method will
increase the power of our efﬁcacy estimates since up to
90% of symptomatic malaria patients may harbour (sub-
microscopic) gametocyte densities prior to the initiation
of treatment.16
Gametocyte density is associated with the likelihood of
mosquito infection and some of the lowest gametocyte
densities may therefore be unlikely to result in mosquito
infections. In general, there are limitations to which
gametocyte prevalence or density can be used to predict
mosquito infection rates. The ﬁtness or infectivity of
gametocytes is variable, especially after treatment.19 52 53
Very early studies demonstrated that primaquine may
render gametocytes non-infectious several days before
they are cleared from the circulation.30 54 55 The only
approach to directly measure transmission-blocking
potential involves assessing the infectiousness of the par-
ticipant’s blood to mosquitoes using the membrane
feeding assay or direct skin feeding assays,56 the latter
being described by early malariologists.57 58 However,
the capacity for mosquito feeding assays is not widely
available and repeated assessments of infectiousness on
the same patients have never been performed as part of
clinical trials. This is partly because of ethical concerns
related to repeated venous bleeding in young children,
and partly because of the complexity of mosquito hus-
bandry when large numbers of mosquitoes are required
for robust transmission estimates.59 In the absence of
biomarkers, using the prevalence and density of gameto-
cytes after treatment is the most pragmatic approach to
assess the transmission-blocking efﬁcacy of drugs across
a variety of malaria endemic settings.
To assess the safety of the 8-aminoquinoline drugs,
there must be a clear deﬁnition of the risk of haemolysis
and how it should be measured.31 60 The safety proﬁle
may best be deﬁned by the incidence of endpoints that
could compromise health, such as signs of severe haem-
olysis, and the need for interventions such as haematinic
drug administration, hospitalisation or blood transfu-
sion. These events, however, are rare and changes in
haemoglobin concentration may be a more sensitive
primary safety outcome for standard clinical trials. In a
recent Cochrane review of randomised controlled trials
of primaquine’s efﬁcacy, only one trial25 was found to
have measured the haemoglobin concentration to assess
safety.61 In this current study, clinically relevant safety
endpoints have been selected and a standardised pro-
cedure is in place for the investigation and management
of severe haemolysis. A shortcoming of the current study
is that safety data are most urgently needed in the most
vulnerable group, G6PD-deﬁcient individuals. For
ethical reasons this group was excluded. The authors
consider that the priority is ﬁrst to determine the
minimal effective dose in a G6PD normal population
before G6PD-deﬁcient individuals are exposed to this
low dose of primaquine to assess safety.
The ultimate evidence for a beneﬁcial role of prima-
quine in reducing malaria transmission would come
from trials assessing the effect of the drug on measures
of community-level transmission. Once a safe and efﬁca-
cious dose of primaquine in combination with ACTs is
established, the next step involves designing these com-
munity trials. Treatment of symptomatic cases could play
an important role in reducing the spread of (resistant)
malaria strains from symptomatic patients.62 However,
because of the large pool of asymptomatic parasite car-
riers in all endemic settings63 and their importance in
deﬁning transmission potential, any effect of prima-
quine on community-wide transmission will be limited if
administration is restricted to symptomatic cases. Other
strategies such as pro-active screening and treatment
and (focal) mass drug administration may have a larger
impact in some settings.64 This trial forms the starting
point for deﬁning the optimal dose of primaquine for
use in transmission-blocking interventions.
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